BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial

Reuters12-18

BRIEF-<a href="https://laohu8.com/S/ARFXD">Promis Neurosciences</a> Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial

Dec 18 (Reuters) - ProMIS Neurosciences Inc PMN.O:

PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASE
PROMIS NEUROSCIENCES INC - INTERIM ANALYSIS EXPECTED IN Q2 2026, FINAL RESULTS IN Q4 2026

Source text: ID:nGNX95lDlK

Further company coverage: PMN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592055849?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592055849","market":"nz","top_or_hot":-1,"title":"BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ARFXD\">Promis Neurosciences</a> Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial </title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a> <span>PMN.O</span>:</p><ul><li><p>PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASE</p></li><li><p>PROMIS NEUROSCIENCES INC - INTERIM ANALYSIS EXPECTED IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, FINAL RESULTS IN Q4 2026</p></li></ul><p>Source text: <span>ID:nGNX95lDlK</span></p><p>Further company coverage: <span>PMN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 20:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ARFXD\">Promis Neurosciences</a> Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial </title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a> <span>PMN.O</span>:</p><ul><li><p>PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASE</p></li><li><p>PROMIS NEUROSCIENCES INC - INTERIM ANALYSIS EXPECTED IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, FINAL RESULTS IN Q4 2026</p></li></ul><p>Source text: <span>ID:nGNX95lDlK</span></p><p>Further company coverage: <span>PMN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA17JLKX:1","article_id":"2592055849","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592055849","pubTimestamp":1766061565,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial Dec 18 (Reuters) - ProMIS Neurosciences Inc PMN.O:PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PMN":"ProMIS Neurosciences Inc"},"translate_title":"BRIEF-Promis Neurosciences在Precise-AD 1b期Cli试验中超额入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMN":0.9},"content_text":"BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial Dec 18 (Reuters) - ProMIS Neurosciences Inc PMN.O:PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASEPROMIS NEUROSCIENCES INC - INTERIM ANALYSIS EXPECTED IN Q2 2026, FINAL RESULTS IN Q4 2026Source text: ID:nGNX95lDlKFurther company coverage: PMN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592055849","isCrawlerRequest":true}